Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial

Nenhuma Miniatura disponível
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
TASCILAR, Koray
HAGEN, Melanie
KLEYER, Arnd
SIMON, David
REISER, Michaela
HUEBER, Axel J.
MANGER, Bernhard
ENGLBRECHT, Matthias
FINZEL, Stephanie
TONY, Hans-Peter
Citação
LANCET RHEUMATOLOGY, v.3, n.11, p.E767-E777, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Owing to increasing remission rates, the management of patients with rheumatoid arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing Remission (RETRO) study investigated tapering and withdrawal of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis in stable remission to test whether remission could be retained without the need to take DMARD therapy despite an absence of symptoms. Methods RETRO was an investigator-initiated, multicentre, prospective, randomised, controlled, open-label, parallel group phase 3 trial in patients aged at least 18 years with rheumatoid arthritis for at least 12 months before randomisation who were in sustained Disease Activity Score using 28 joints with erythrocyte sedimentation rate (ESR) remission (score <2middot6 units). Eligible patients were recruited consecutively from 14 German hospitals or rheumatology practices and randomly assigned (1:1:1) without stratification and regardless of baseline treatment, using a sequence that was computer-generated by the study statistician, to continue 100% dose DMARD (continue group), taper to 50% dose DMARD (taper group), or 50% dose DMARD for 6 months before stopping DMARDs (stop group). Neither patients nor investigators were masked to the treatment assignment. Patients were assessed every 3 months and screened for disease activity and relapse. The primary endpoint was the proportion of patients in sustained DAS28-ESR remission without relapse at 12 months, analysed using a log-rank test of trend and Cox regression. Analysis by a trained statistician of the primary outcome and safety was done in a modified intention-to treat population that included participants with non-missing baseline data. This study is completed and closed to new participants and is registered with ClinicalTrials.gov (NCT02779114). Findings Between May 26, 2010, and May 29, 2018, 303 patients were enrolled and allocated to continue (n=100), taper (n=102), or stop DMARDs (n=101). 282 (93%) of 303 patients were analysed (93 [93%] of 100 for continue, 93 [91%] of 102 for taper, and 96 [95%] of 101 for stop). Remission was maintained at 12 months by 81middot2% (95% CI 73middot3-90middot0) in the continue group, 58middot6% (49middot2-70middot0) in the taper group, and 43middot3% (34middot6-55middot5) in the stop group (p=0middot0005 with log-rank test for trend). Hazard ratios for relapse were 3middot02 (1middot69-5middot40; p=0middot0003) for the taper group and 4middot34 (2middot48-7middot60; p<0.0001)) for the stop group, in comparison with the continue group. The majority of patients who relapsed regained remission after reintroduction of 100% dose DMARDs. Serious adverse events occurred in ten of 93 (11%) patients in the continue group, seven of 93 (8%) patients in taper group, and 13 of 96 (14%) patients in the stop group. None were considered to be related to the intervention. The most frequent type of serious adverse event was injuries or procedural complications (n=9). Interpretation Reducing antirheumatic drugs in patients with rheumatoid arthritis in stable remission is feasible, with maintenance of remission occurring in about half of the patients. Because relapse rates were significantly higher in patients who tapered or stopped antirheumatic drugs than in patients who continued with a 100% dose, such approaches will require tight monitoring of disease activity. However, remission was regained after reintroduction of antirheumatic treatments in most of those who relapsed in this study. These results might help to prevent overtreatment in a substantial number of patients with rheumatoid arthritis. Funding None.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/44084
Referências
  1. Aga AB, 2015, ANN RHEUM DIS, V74, P381, DOI 10.1136/annrheumdis-2013-204020
  2. Ajeganova S, 2016, ANN RHEUM DIS, V75, P867, DOI 10.1136/annrheumdis-2014-207080
  3. Albrecht K, 2016, Z RHEUMATOL, V75, P90, DOI 10.1007/s00393-015-0019-5
  4. ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
  5. Chatzidionysiou K, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000133
  6. Combe B, 2013, J RHEUMATOL, V40, P1650, DOI 10.3899/jrheum.121515
  7. Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, P759, DOI 10.1002/art.41589
  8. Emery P, 2020, ANN RHEUM DIS, V79, P1023, DOI 10.1136/annrheumdis-2020-217246
  9. Emery P, 2014, NEW ENGL J MED, V371, P1781, DOI 10.1056/NEJMoa1316133
  10. Fautrel B, 2016, ANN RHEUM DIS, V75, P59, DOI 10.1136/annrheumdis-2014-206696
  11. Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI [10.1136/ard.2011.149765, 10.1002/art.30129]
  12. Haschka J, 2016, ANN RHEUM DIS, V75, P45, DOI 10.1136/annrheumdis-2014-206439
  13. Huizinga TWJ, 2015, ANN RHEUM DIS, V74, P35, DOI 10.1136/annrheumdis-2014-205752
  14. Kaneko Y, 2018, ANN RHEUM DIS, V77, P1268, DOI 10.1136/annrheumdis-2018-213416
  15. Klarenbeek NB, 2011, ANN RHEUM DIS, V70, P315, DOI 10.1136/ard.2010.136556
  16. Marotte H, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2019-215546
  17. McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
  18. Nam JL, 2014, ANN RHEUM DIS, V73, P75, DOI 10.1136/annrheumdis-2013-203440
  19. PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
  20. Saleem B, 2010, ANN RHEUM DIS, V69, P1636, DOI 10.1136/ard.2009.117341
  21. Sanmarti R, 2019, ARTHRITIS RHEUMATOL, V71, P1616, DOI 10.1002/art.40905
  22. Schett G, 2021, NAT REV RHEUMATOL, V17, P135, DOI 10.1038/s41584-020-00543-5
  23. Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis-2019-216655
  24. Smolen JS, 2014, LANCET, V383, P321, DOI 10.1016/S0140-6736(13)61751-1
  25. Smolen JS, 2013, LANCET, V381, P918, DOI 10.1016/S0140-6736(12)61811-X
  26. Tanaka Y, 2020, ANN RHEUM DIS, V79, P94, DOI 10.1136/annrheumdis-2019-216169
  27. Tanaka Y, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1937-4
  28. tenWolde S, 1996, LANCET, V347, P347, DOI 10.1016/S0140-6736(96)90535-8
  29. van Mulligen E, 2020, ANN RHEUM DIS, V79, P1174, DOI 10.1136/annrheumdis-2020-217485
  30. van Nies JAB, 2015, ANN RHEUM DIS, V74, P806, DOI 10.1136/annrheumdis-2014-206047
  31. Vittecoq O, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031467

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17